Alterations in Tissue Metabolite Profiles with Amifostine-Prophylaxed Mice Exposed to Gamma Radiation
Abstract
Acute exposure to high-dose ionizing irradiation has the potential to severely injure the hematopoietic system and its capacity to produce vital blood cells that innately serve to ward off infections and excessive bleeding. Developing a medical radiation countermeasure that can protect individuals from the damaging effects of irradiation remains a significant, unmet need and an area of great public health interest and concern. Despite significant advancements in the field of radiation countermeasure development to find a nontoxic and effective prophylactic agent for acute radiation syndrome, no such drug has yet been approved by the Food and Drug Administration. This study focuses on examining the metabolic corrections elicited by amifostine, a potent radioprotector, on tissues of vital body organs, such as the heart, spleen, and kidney. Our findings indicate that prophylaxis with this drug offers significant protection against potentially lethal radiation injury, in part, by correction of radiation-induced metabolic pathway perturbations.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 21, 2020
- Source ID
- 10.3390/metabo10050211
Entities
People
- Amrita K. Cheema
- Meth Jayatilake
- Michael Girgis
- Oluseyi O. Fatanmi
- Stephen Y. Wise
- Thomas M. Seed
- Vijay K Singh
- Yaoxiang Li
Organizations
- Armed Forces Radiobiology Research Institute